AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Replication factor C subunit 5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P40937

UPID:

RFC5_HUMAN

Alternative names:

Activator 1 36 kDa subunit; Activator 1 subunit 5; Replication factor C 36 kDa subunit

Alternative UPACC:

P40937; A8MZ62; B3KSX8

Background:

Replication factor C subunit 5 (RFC5), also known by its alternative names such as Activator 1 36 kDa subunit, plays a crucial role in DNA replication and repair. It functions as a part of the complex machinery that elongates primed DNA templates by DNA polymerase delta and epsilon, necessitating the action of accessory proteins like PCNA and activator 1. This protein's involvement in the fundamental process of DNA synthesis positions it as a key player in cellular proliferation and genome stability.

Therapeutic significance:

Understanding the role of Replication factor C subunit 5 could open doors to potential therapeutic strategies. Its pivotal role in DNA replication and repair mechanisms makes it a promising target for developing novel treatments for diseases characterized by genomic instability.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.